Products

PAS CAP (Capecitabine Tablets IP 500mg) is an oral chemotherapy medication classified as a fluoropyrimidine carbamate, acting as a prodrug of 5-fluorouracil (5-FU). This targeted design allows PAS CAP to be selectively activated within tumor tissue, helping minimize systemic toxicity while delivering effective anticancer results.

The mechanism of CAPECITABINE TABLETS IP 500mg — PAS CAP disrupts DNA synthesis and RNA processing, ultimately leading to cancer cell death.

• Strengths Available: 150 mg & 500 mg
• Formulation: Film-coated tablets
• Marketed by: PASKLS Pharma
• Manufactured at: WHO-GMP Certified Facility, Himachal Pradesh, India

PAS NIB (Imatinib Tablets IP 100 mg / 400 mg) is a selective tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and other malignancies associated with abnormal tyrosine kinase activity.

PAS NIB works by inhibiting BCR-ABL tyrosine kinase, as well as PDGF and c-KIT receptors, thereby blocking cancer cell proliferation and inducing apoptosis in malignant cells.

• Strengths Available: 100 mg & 400 mg
• Formulation: Film-coated tablets
• Indication: CML, ALL & other kinase-driven cancers
• Bioavailability: ~98% (oral)